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Progress in molecular high-throughput techniques has led to the opportunity of a
comprehensive monitoring of biomolecules in medical samples. In the era of personalized
medicine, these data form the basis for the development of diagnostic, prognostic and pre-
dictive tests for cancer. Because of the high number of features that are measured simulta-
neously in a relatively low number of samples, supervised learning approaches are sensitive
to overfitting and performance overestimation. Bioinformatic methods were developed to
cope with these problems including control of accuaracy and precision. However, there is
demand for easy-to-use software that integrates methods for classifier construction, per-
formance assessment and development of diagnostic tests. To contribute to filling of this
gap, we developed a comprehensive R package for the development and validation of diag-
nostic tests from high-dimensional molecular data. An important focus of the package is
a careful validation of the classification results. To this end, we implemented an extended
version of the multiple random validation protocol, a validation method that was intro-
duced before. The package includes methods for continuous prediction scores. This is
important in a clinical setting, because scores can be converted to probabilities and help
to distinguish between clear-cut and borderline classification results. The functionality of
the package is illustrated by the analysis of two cancer microarray data sets.
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1. Introduction
Ongoing progress in the molecular analysis techniques for biological samples has led to
the advancement of high-throughput methods for genomics, transcriptomics, proteomics,
metabolomics and other -omics fields (Ellis et al. 2007; Service 2008; Shi et al. 2006; Stratton
et al. 2009). Microarrays, for example, allow the simultaneous monitoring of virtually all genes
that may be expressed in a tumor sample. Data sets generated by high-throughput meth-
ods are typically high-dimensional in the number of molecules (some hundreds to some ten
thousands), but often include only a limited number of samples (some tens to some hundreds).
Since the early days of microarrays, much attention has been paid to the problem of class
prediction by gene expression profiles. In 1999, a landmark study on gene expression of
haematological malignancies showed discrimination of acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL) with high precision (Golub et al. 1999). More recent
studies focus on the identification of molecular signatures that are prognostic for disease out-
come in breast, lung, colorectal, and others cancers (Denkert et al. 2009; Fritzmann et al.
2009; Chen et al. 2007; Roepman et al. 2005; Van de Vijver et al. 2002). Further molecular
signatures were identified that predict the response to therapies, for example the success of
neoadjuvant treatment for breast cancer (Ayers et al. 2004; Farmer et al. 2009; Liedtke et al.
2009). The aim of such investigations is the development of molecular tests that refine can-
cer stratification and lead to individual, patient-tailored therapies with effective treatment
and a minimum of adverse side effects from the therapy. For breast cancer, gene expression
based prognostic tests are already used in clinical practice. Two commercially available as-
says, Mammaprint® and OncotypeDX®, are currently being validated in large clinical trials
(Sparano 2006; Cardoso et al. 2007). More recently, Endopredict® was developed and shown
to be reproducible between molecular pathology laboratories (Filipits et al. 2011; Denkert
et al. 2012).
The methodical challenges associated with class prediction from high-dimensional data in-
clude (i) selection of the features (genes, proteins, metabolites, . . . ) relevant for the problem
and (ii) avoidance of overfitting and overestimation of results by using appropriate methods
for classifier construction and error estimation. Feature selection identifies the informative
markers out of thousands or ten-thousands of measurements. As a consequence, the signal-to-
noise ratio in the data is increased, leading to more precise test results. Further, a molecular
test that is sparse in the number of features is easier and cheaper to implement.
The critical point for correct interpretation of a classification study is an appropriate method-
ology for error estimation and validation (Lottaz et al. 2008). Many molecular studies apply
cross-validation and in particular the leave-one-out approach for estimation of the error rate.
This approach gives a nearly unbiased estimate of the errors rate, but can be imprecise: it has
a high variability and can produce large outliers (Braga-Neto and Dougherty 2004; Braga-Neto
et al. 2004; Efron and Tibshirani 1997). In molecular studies, often an optimal classifier is
selected after comparing the performance of a large number of classifiers that include different
sets of genes. Combination of such a classifier optimization procedure with cross-validation
suffers from the variance of error rates and can lead to overfitting and overestimation of the
classifier performance. Another common validation method is based on a fixed split of the
data in training and test sets.
However, a recent meta-analysis of studies on cancer outcome has shown a critical dependence
of classification results on the split of the data in training and test sets (Michiels et al. 2005).
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In this work, a new multiple random validation strategy was introduced that is based on
repeated drawing of training sets of different size. In n-fold cross-validation of N samples, the
size of the training set is (1 − 1/n)N . Different than in cross-validation protocols where the
training set size is fixed, in the multiple random validation protocol the performance is studied
for a multitude of training sets of different size. In this way, the multiple random protocol can
be considered as generalization of cross-validation. Studying the classification performance
for several training set sizes can help to detect how many samples are necessary for good or
for optimal classification results. Therefore, we included multiple random validation in the
software.
Many of the classification methods that are common in the field of machine learning have been
applied to high-dimensional molecular data. These include nearest-centroid-classification,
linear discriminant analysis, classification trees, and more complex methods such as support
vector machines, neural networks, or partial least squares. Many of the classification methods
are available in R (R Core Team 2014), a programming language and statistical environment
shown to be extremely convenient for the analysis of high-dimensional molecular data. It
turned out that good results can often be obtained by simple methods, such as nearest-
centroid-classification. Indeed, simple classifiers have been shown to perform equally or better
in direct comparison to more complex methods (Wessels et al. 2005; Dudoit et al. 2002).
In recent years, methods for pattern recognition have been adapted to the analysis of high-
dimensional molecular data. For example, nearest shrunken centroid classification (Tibshirani
et al. 2002) combines a soft thresholding method for feature selection with nearest centroid
classification. However, there is need for a simple to use software for predictor optimization,
reliable estimation of error rates and trade-off between sensitivity and specificity in a uniform
framework.
The MicroArray Quality Control (MAQC)-II (Shi et al. 2010) study showed that, for genera-
tion of predictive models, good modeling practice was more important than the actual choice
of a particular algorithm. To contribute to the availability of state-of-the-art modeling tools
to the biomedical community, we developed cancerclass (Budczies and Kosztyla 2011a), a
comprehensive R package for development and validation of diagnostic tests. An important
focus of the package is a careful validation of the classification results and it therefore includes
the recently introduced multiple random validation protocol. Multiple random validation can
be considered as more comprehensive than cross-validation, because it allows to study the
prediction accuracy in dependence of the training set size. A second important focus of the
package is inclusion of continuous prediction scores. Continuous scores are important in a
clinical setting, because they are convertible to class membership probabilities and help to
distinguish between clear-cut and borderline classification results. The functionality of the
package is illustrated by the analysis of two cancer microarray data sets.
2. Implementation
cancerclass is freely available from the Bioconductor repository (http://www.Bioconductor.
org/).
2.1. Architecture
Table 1 gives an overview of the main classes and methods. The package was implemented in




Description Input class(es) Output class Plot methods
for output
class
validate() Construction and valida-
tion of predictors in de-
pendence of the training
set size.
‘ExpressionSet’ ‘validation’ xy, genes,
samples
nvalidate() Construction and valida-
tion of predictors in de-
pendence of the number
of genes.
‘ExpressionSet’ ‘nvalidation’ xy, genes,
samples
fit() Construction of a predic-
tor from a training data
set.
‘ExpressionSet’ ‘predictor’ genes
predict() Calculation of continuous
prediction scores in a test
















Table 1: Methods for predictor construction and validation. All methods need an object of the
class ‘ExpressionSet’ as input that includes an expression data set and information about
class membership, for example clinical outcome. The functions validate() and nvalidate()
perform classification in a multiple random validation protocol. The functions fit() and
validate() implement training and validation using a fixed split in training and test data.
The function loo() performs leave-one-out cross-validation. For most of the output classes,
there are several plot methods that can be selected by the parameter type.
an object-orientated programming style. Most of the functions have instances of S4 classes
as input and output objects. S4 is the up-to-date method for object-oriented programming
in R, described and implemented in the package methods (R Core Team 2014).
The molecular data are stored in ‘ExpressionSet’ objects, as they are defined in the R
package Biobase (Gentleman et al. 2004). These objects contain a matrix of expression data
integrated with phenotype and array probe annotations. For the example data sets delivered
with the package (see below), the data frame describing the phenotype contains a column
"class", a binary variable that is used for classification. Most of the output objects can be
visualized using the generic function plot that has specialized methods for the results of a
classification task. Often, the user can select between different kinds of plots by an additional
parameter type that is passed to the plot function.
2.2. Classification protocol
The classification protocol includes the following three steps: feature selection, predictor
construction using the nearest centroid method, and validation. Various statistics are available
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to rank the features and to select a set of top array probes. These include fold change, t test,
Wilcoxon test, or different versions of outlier statistics like os, ort, and copa (Tibshirani
and Hastie 2007; Wu 2007). Feature selection is always conducted using only the training
data, and not the complete data. This procedure is known to be necessary to obtain reliable
misclassification rates (Simon et al. 2003; Ambroise and McLachlan 2002; West et al. 2001).
For high-dimensional data, feature selection is the computational most demanding part of the
classification procedure. Therefore, we implemented this step using external C code that is
integrated into the package using the .C interface.
The implemented methods for validation include the multiple random validation protocol
(functions validate and nvalidate) that was introduced in Michiels et al. (2005). Following
this protocol, a large number of training sets of different size is drawn. For each of these
training sets, a predictor is constructed and evaluated on the remaining samples. The protocol
works with balanced training data sets that contain an equal number of patients from each of
the classes. For a fixed size of training data sets, a mean misclassification rate and confidence
intervals are estimated from the distribution of the classification results. Further, we have
implemented functions for validation using a fixed training-test split (fit and validate) as
well as leave-one-out cross-validation (loo).
2.3. Nearest centroid classification
Classification is done with the nearest centroid method: First, the centroids in the space
of selected features are calculated for both classes. Then, the distance of the test sample
to the centroids is calculated and the test sample is predicted to belong to the class with
the nearest centroid. cancerclass offers four different similarity measures for calculation of
the distance that can be specified by dist = "euclidean", "center", "angle", "cor".
All four similarity measures can be derived from the euclidean metric by centering and/or
scaling of centroids and test sample before calculating the distance. In detail, starting from
an expression vector x, the centered, scaled and the centered-scaled vectors are denoted by
xc = x − x̄, xs = x/‖x‖ and xcs = (x − x̄)/‖x − x̄‖. Then, the four similarity measures are
defined by
deuclidean(x, y) = ‖x− y‖, (1)
dcenter (x, y) = ‖xs − ys‖, (2)
dangle(x, y) = ‖xc − yc‖ =
√
1− cos angle(x, y), (3)
dcor (x, y) = ‖xcs − ycs‖ =
√
1− cor(x, y). (4)
As stated above, the last two similarity measures can be expressed in terms of the geometric
angle or the Pearson correlation coefficient, respectively.
2.4. Continuous prediction score
In context of clinical applications, it can be advantageous to work with a continuous prediction
score rather than a clear-cut answer “yes” or “no” for class membership. cancerclass offers
three different continuous prediction scores z, ζ and ξ. When c1 and c2 are the centroids of
the two classes and x is a test sample,
z =
d(x, c1)− d(x, c2)
d(c1, c2)
(5)
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is the logarithm of the ratio of the distances of the test sample and the centroids of the two
classes. All three scores are negative, if the test sample is closer to the centroid of class 1
than class 2, and positive if this is not so.
2.5. Data sets
cancerclass is delivered with an example data set of leukemia. GOLUB (72 patients, 7129
genes) includes gene expression data of blood and bone marrow of AML and ALL patients
(Golub et al. 1999). Gene expression data of breast cancer tissues are available from an
additional R package cancerdata (Budczies and Kosztyla 2011b). VEER (78 patients, 24481
genes) includes the training data set of Mammaprint® classifier for breast cancer (Van’t Veer
et al. 2002). VIJVER (295 patients, 24481 genes) is a larger breast cancer expression data set
that includes some of the samples of the earlier series (Van de Vijver et al. 2002). VEER1 and
VIJVER1 (4948 genes) are versions of the above data sets after unsupervised filtering of genes
as described in Van’t Veer et al. (2002). All patients of the breast cancer studies underwent
surgery as initial treatment. As in Van de Vijver et al. (2002), patients are divided in a good
prognosis group (NODM) that did not receive adjuvant systemic therapy and remained free
of distant metastases for at least 5 years and a poor prognosis group (DM) that received
adjuvant systemic therapy or not and developed distant metastases within 5 years.
2.6. Statistical methods
The following statistical methods are applied during generation of the plots: Confidence
intervals for proportions are estimated using Wilson’s method as implemented by the function
binom.confint() from the R package binom (Dorai-Raj 2014). To convert the continuous
prediction score to probabilities, logistic regression is executed using the function glm() from
the R package stats (R Core Team 2014).
3. Results
In the examples below, we show how the expression data sets GOLUB and VIJVER can
be analyzed using the methods validate, nvalidate, loo, fit and predict of the package
cancerclass. A short description of the methods is given in Table 1.
3.1. Performance of predictors in dependence of the number of genes
The function nvalidate() allows studying the performance of predictors in dependence of
the numbers of genes. For each number of genes, multiple splits in training and test sets
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Figure 1: Performance of nearest centroid predictors in dependence of the number of genes
and the training set size. Percentage of misclassifications for all patients (with two-sided
90% confidence intervals, black dotted lines) as well as individually for each of the classes
(red and green lines). Prediction of the leukemia subtype using the GOLUB expression data
(A−B). Prediction of breast cancer prognosis (NODM = no distant metastasis within five
years, DM = distant metastasis within 5 years) using the VIJVER expression data (C−D).
Classification performance in dependence of the number of genes in the predictor (A+C).
Learning curves showing the improvement of 50-gene-predictors with growing training set
size (B+D). For each number of genes and each training set size, misclassification rates and
confidence intervals were estimated from 200 randomly drawn training sets.
are drawn randomly. For each split in training and test data set, the top genes that are
included in the predictor are selected by Welch’s t test. By the commands below, predictors
are constructed training sets including 2/3 of the patients and evaluated in test sets including
the remaining 1/3 of patients:
R> library("cancerclass")
R> data("GOLUB", package = "cancerclass")
R> nvalidation <- nvalidate(GOLUB, ngenes = 2:100, ntrain = "balanced",
+ method = "welch.test", dist = "cor")
R> plot(nvalidation, type = "xy")
While this training set size and balanced training sets are the default, the number of patients






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2: Detailed analysis of 50-gene-predictors. Prediction of the leukemia subtype using
the GOLUB expression data (A−B). Prediction of breast cancer prognosis using the VIJVER
expression data (C−D). Performance of predictors for each of the patients with the height
of bars indicating the percentage of predictors that fail in classifying a particular patient
(A+C). The top genes being most frequently included in the predictor with the height of the
bars indicating the percentage of predictors that include a particular gene (B+D). For each
training size set ranging from ten to the maximal possible size, predictors were trained in 200
randomly drawn training sets.
of the two classes in the training sets can be explicitly specified by the parameter ntrain.
Figures 1A and C show the misclassification rates in dependence of the number of genes in
the predictor. Using such kind of diagrams, predictors can be optimized in such a way that
they perform well and are as sparse as possible (in the number of features) at the same time.
3.2. Performance of predictors in dependence of the training set size
Next, we chose a fixed number of genes and study the performance of 50 gene predictors in
dependence of the training set size. This is the original method of multiple random validation
(Michiels et al. 2005).
R> validation <- validate(GOLUB, ngenes = 50, ntrain = "balanced",
+ method = "welch.test", dist = "cor")
R> plot(validation, type = "xy")
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Class 1 (real) Class 2 (real)
Class 1 (pred.) TP FP PPV = TP / (TP + FP)
Class 2 (pred.) FN TN NPV = TN / (TN + FN)
sensitivity = specificity =
TP / (TP + FN) TN / (TN + FP)
Table 2: Performance characteristics for a diagnostic test. The basic quantities in the 2 × 2
table are the number of true positives (TP), the number of false positives (FP), the number of
true negatives (TN), and the number of false negatives (FN). Starting from there, sensitivity,
specificity as well as positive predictive values (PPV) and negative predictive values (NPV)
of the diagnostic test can be estimated.
Figures 1B and D show the misclassification rate in dependence of the number of patients in
the training data set. The rates are calculated for all patients in the test data sets as well as
separately for each of the two classes.
3.3. Detailed analysis of predictors
Two further visualization methods for the ‘validation’ and ‘nvalidation’ objects allow a
more detailed analysis of the predictors:
R> plot(validation, type = "samples")
R> plot(validation, type = "genes", min.percent = 30)
Figures 2A and C show the performance of 50-gene-predictors individually for each of the
patients. Classification of a patient can depend on the training set where a predictor is trained,
or it can fail consistently for most or all predictors, independent of the training set. For the
breast cancer study, prediction of prognosis was feasible for half of the patients consistently
with > 80% of the predictors. However, almost all predictors failed for approximately a
quarter of the patients. For the leukemia study, the predictors performed excellent for almost
all patients, except for 5 ALL cases that were predicted incorrectly by more than 30% of the
predictors.
Figures 2B and D show the genes that were selected in more than 25% of the predictors.
For the leukemia study, 23 top genes were included in more than 50% of the predictors. For
the study on breast cancer, 4 top genes were included in more than 50% of the predictors:
thymidine kinase 1 (TK1), survivin (BIRC5), protein regulator of cytokinesis (PRC1), and
separase (KIAA0165). In addition to binary class prediction, cancerclass has methods for
the construction and validation of continuous prediction scores that are discussed in the next
three subsections.
3.4. Continuous prediction score: Leave-one-out cross-validation
Using the GOLUB data, we perform leave-one-out cross-validation:
R> cv <- loo(GOLUB, positive = "ALL", method = "welch.test", dist = "cor")
R> plot(cv, type = "histogram", score = "zeta")
R> plot(cv, type = "curves", score = "zeta")
R> plot(cv, type = "roc", score = "zeta")
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Figure 3: Performance of continuous 50-gene-predictors. The leukemia data were analyzed
using leave-one-out cross-validation (A−C), the breast cancer data using a training-test ap-
proach (D−F). Histograms of the prediction score (A+D), sensitivity, specificity, PPV and
NPV in dependence of the prediction score (B+E), ROC curves (C+F). The prediction score
was significantly different between the two classes for both classification problems (histograms:
p value from Welch’s t test). In the ROC plots, 95% confidence intervals for sensitivity (red
lines) and specificity (green lines) were calculated by Wilson’s method.
The distribution of the prediction scores ζ for ALL and AML patients is shown in Figure 3A.
An overview on the common accuracy measures for diagnostic tests is given in Table 2. Sen-
sitivity and specificity are usually of primary interest, because they do not depend on the
prevalence of the classes in a population. The parameter positive, here set to "ALL", al-
lows to select the class that we would like to detect. Figure 3B shows sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV) in dependence on the
cutoff value for the prediction score. Furthermore, cancerclass can calculate receiver oper-
ating characteristic (ROC) curves to visualize sensitivity and specificity of diagnostic tests
(Figure 3C).
3.5. Continuous prediction score: Training and test set
Using the breast cancer data, we show how cancerclass works in a training-test setting. The
predictor is trained on VEER1, the same training set that was used in Van’t Veer et al. (2002).
The test set comprises the patients of VIJVER1 that are not in VEER1:
R> library("cancerclass")
R> data("VEER1", package = "cancerdata")
R> data("VIJVER1", package = "cancerdata")
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Figure 4: Probability of class membership calculated from continuous 50-gene predictors. The
probability (with 95% confidence intervals) for membership in the poor prognosis class was
estimated by logistic regression. Tracks at the top and the bottom of the graphics show the
density of patients having a poor and good prognosis, respectively. Hazard for having ALL
obtained from the GOLUB data (A). Hazard for developing a distant metastasis obtained
from the VIJVER data (B).
R> VIJVER2 <- VIJVER1[, setdiff(sampleNames(VIJVER1), sampleNames(VEER1))]
R> predictor <- fit(VEER1, method = "welch.test")
R> prediction <- predict(predictor, VIJVER2, "DM", ngenes = 50, dist = "cor")
R> plot(prediction, type = "histogram", score = "zeta")
R> plot(prediction, type = "curves", score = "zeta")
R> plot(prediction, type = "roc", score = "zeta")
Again, the prediction score ζ and its correlation with the clinical outcome can be visualized
in a histogram, plots of sensitivity and specificity, and a ROC curve (Figures 3D–F).
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3.6. Conversion of prediction scores to risks
To assess the risk of a patient for a poorer course of the disease, it is desirable to convert the
continuous prediction parameter into a probability for class membership. In case of the breast
cancer study, this can be interpreted as hazard for a patient to develop a distant metastasis
within 5 years. Having large data sets at hand, this hazard could be estimated by the incidence
of distance metastases within a small interval around the value of ζ. However, usually this
is not possible because the number of samples analyzed in high-throughput studies is small.
For a limited number of patients, cancerclass allows the estimation of the hazard by logistic
regression:
R> plot(cv, type = "logistic", score = "zeta")
Using this method, Figures 4A and B show the probability of ALL and the probability of a
distance metastasis in dependence of ζ.
4. Discussion
The high-dimensionality of molecular data sets leads to methodic challenges for supervised
learning. Overfitting should be avoided and misclassification rates should be estimated re-
alistically in order to prevent an overoptimistic interpretation of results. cancerclass is a
comprehensive R package for the development and validation of diagnostic tests from high-
dimensional molecular data: Misclassification rates can be studied in dependence of the num-
ber of genes in the predictor and the size of the training set. ROC curves help to trade
sensitivity off against specificity. As it is important for a realistic interpretation of results,
misclassification rates, sensitivity and specificity are delivered as point estimates with confi-
dence intervals.
A multitude of methods were developed to tackle the classification problem and many of
them were applied to high-dimensional molecular data. The MicroArray Quality Control
(MAQC)-II study (Shi et al. 2010) showed that the prediction performance depended on
the proficiency of the analysis team, but not on the particular model choice, as many of the
models performed equally. The models differed concerning algorithms and/or parameters and
often simple methods performed as well as more complicated methods (Popovici et al. 2010).
Good modeling practice appeared to be more important than the actual choice of a particular
algorithm. In cancerclass we combined a simple classification algorithm with a comprehensive
set of validation and visualization methods. In principle, it is possible to replace the nearest
centroid classifier by any other classification algorithms, but this requires changes in the R
code.
It is an advantage of nearest centroid classification that it can handle balanced and unbalanced
data sets without any problems. Estimation of centroids remains unbiased in the unbalanced
case. However, using balanced training data can be considered as optimal when the biological
variance is unknown or known and comparable for both classes. If the biological variance is
equal for both classes, both centroids are estimated with the same precision, if the training
set is balanced. Thus, we used balanced training sets in the example studies. However, the
methods of cancerclass are capable to handle arbitrary kinds of training sets.
As examples, we analyzed two expression data sets on human cancer that were published
before. Since the appearance of Golub’s work on leukemia (Golub et al. 1999), it is well-known
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that AML and ALL can be distinguished using gene expression profiling with high accuracy
of about 95%. Here, we could reproduce the results of the AML vs. ALL classification with
sensitivity and specificity around 95%. The ROC curve obtained from continuous scores in
leave-one-out cross-validation yields an almost perfect separation (AUC = 0.994).
As a second example, we studied the prediction of breast cancer prognosis by expression data
in the tumor tissue. Using the multiple random validation protocol, we were able to obtain
sensitivities and specificities for the prediction of distant metastasis in the range of 60%–70%.
Van’t Veer et al. (2002) published classification accuracies of 83% in a cohort of 78 nodal-
negative patients in a leave-one-out cross-validation and of 89% in an independent validation
set of 19 young node-negative patients (Van’t Veer et al. 2002). However, in a larger validation
series of 180 patients, a sensitivity of 93%, a specificity of 53% and an overall accuracy of
62% were obtained (Van de Vijver et al. 2002). Using cancerclass a 50-gene-predictor was
trained on the same data set as in the original publication (Van’t Veer et al. 2002). Within
statistical variation, the results for the larger validation series agreed with the previously
published results, as indicated by the course of the ROC curve (Figure 3F).
Interestingly, the top 4 genes that are included in most of the 50-gene-predictors constructed
from the VIJVER data set are all known cancer markers: Thymidine kinase 1 (TK1) levels
are elevated in the serum of patients with breast cancer (Carlsson et al. 2009) and other
cancers (Chen et al. 2010). Further, TK1 is a prognostic marker for ovarian cancer (Fujiwaki
et al. 2002). Survivin (BIRC5) is known as inhibitor of metastasis, overexpressed in almost all
cancers, and associated with advanced disease, high grade, abbreviated survival, resistance to
therapy, and accelerated recurrences (Andersen et al. 2007). Protein regulator of cytokinesis
(PRC1) is overexpressed in breast cancer cells while it is undetectable in most of the nor-
mal human tissues (Shimo et al. 2007). Overexpression of separase (KIAA0165) can induce
aneuploidy and mammary tumorigenesis (Zhang et al. 2008).
In summary, we observed a substantially different performance of molecular tests comparing
the leukemia and the breast cancer study. This was expected, as AML and ALL represent
genetically different diseases, while distant metastasis formation in breast cancer is a complex
biological process potentially driven by multiple genetic, epigenetic and environmental factors.
Thus, although gene expression monitoring contributes to its solution, metastasis prediction
is a multifactorial problem that is not easy to solve.
5. Conclusions
We presented an R package for the development and validation of diagnostic tests from high-
dimensional molecular data. cancerclass is freely available from the Bioconductor repository
(http://www.Bioconductor.org/). Important foci of the implementation are methods for
a careful validation that include the multiple random validation protocol and methods for
calculation and visualization of continuous prediction scores. The latter methods, including
ROC curves, are in particular helpful when translating a molecular test into clinics, where
sensitivity and specificity need to be balanced by choosing a suitable cutoff for the prediction
score.
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